Review

An overview of the bioactive compounds, therapeutic properties and toxic effects of apitoxin

Ananias Pascoal\textsuperscript{a}, Maria Manuela Estevinho\textsuperscript{b}, Altino Branco Choupina\textsuperscript{c}, Mário Sousa-Pimenta\textsuperscript{d}, Leticia M. Estevinho\textsuperscript{a,c}\textsuperscript{*}

\textsuperscript{a} Mountain Research Center (CIMO), Polytechnic Institute of Bragança, Campus Santa Apolónia, 5300-253, Bragança, Portugal
\textsuperscript{b} Department of Biomedicine, Unit of Pharmacology and Therapeutics, Faculty of Medicine, University of Porto, Porto, Portugal
\textsuperscript{c} Department of Onco-Hematology, Portuguese Institute of Oncology of Porto (IPO-Porto), 4200-072, Portugal
\textsuperscript{d} Department of Biomedicine, Polytechnic Institute of Bragança, Campus Santa Apolónia, 5300-253, Bragança, Portugal

\textsuperscript{*} Corresponding author. Department of Biology and Biotechnology, Agricultural College of Bragança, Polytechnic Institute of Bragança, Campus Santa Apolónia, 5300-253, Bragança, Portugal

E-mail address: leticia@ipb.pt (L.M. Estevinho).

\url{https://doi.org/10.1016/j.fct.2019.110864}

Received 25 August 2019; Received in revised form 26 September 2019; Accepted 27 September 2019

1. Introduction

Apitoxin, also known as bee venom (BV), is produced in two specialized abdominal glands of worker bees and is used as a defence weapon of bees’ colony (Choi et al., 2015; Zhang et al., 2016). In addition, this natural product has been used since the ancient times to relieve pain and to treat chronic inflammatory diseases such as rheumatoid arthritis, tendinitis, bursitis, skin conditions and even neurological disorders (Moreno and Giralt, 2015).

This natural product is a light-yellow liquid, characterized by a bitter taste, pungent smell and a pH ranging from 4.5 to 5.5 (Eze et al., 2016; Hossen et al., 2017). Some studies have described that 88% of BV is water, yet its specific composition varies depending on bee’ species and season (Moreno and Giralt, 2015). Indeed, BV has been reported to contain a complex of biologically active compounds among which enzymes (phospholipase A\textsubscript{2} [PLA\textsubscript{2}], lysophospholipase, hyaluronidase, acid phosphomonoesterase; α-glucosidase, dipeptidyl peptidase IV and vitellogenin), peptides (melittin [MLT], apamin, mast cell degranulating [MCD], mastocytolytic peptide, scapin, adipalin, minminine; apidaecin; tertiapin; melittin F; diodep; procamine A, B, pamine, and protease-inhibitors), biogenic amines (histamine, dopamine, noradrenaline, nor-epinephrine, neurotransmitters) and other compounds such as amino acids (γ-aminobutyric acid, α-amino acids), carbohydrates (glucose, fructose), pheromones (iso-pentyl acetate, n-butyl acetate, iso-pentanol, n-hexyl acetate, n-octyl acetate, 2-nonanol, n-decyl acetate, benzyl acetate, benzyl alcohol and (2)-11–eicosan-1-ol) and minerals (P, Ca and Mg) (Nguyen et al., 2015; Tustimire et al., 2015; Rady et al., 2017; Moga et al., 2018; Lee et al., 2018). Among these compounds, MLT is the main therapeutic ingredient of BV, representing between 40 and 60% of the dry weight (Abd-Elhakim et al., 2014).

However, it is important to take into account that some BV constituents (such as PLA\textsubscript{2}, lysophospholipase, hyaluronidase, MLT, apamin and MCD) can exert toxic effects, leading to clinical signs and symptoms of envenomation. On the other hand, other compounds, like phosphatase and α-glucosidase, are non-toxic (Cornara et al., 2017).

BV may be obtained from the beehives using electric stunning devices. After, impurities and residues are removed and the remaining purified compound is lyophilized (Han et al., 2013a). In nature, bee venom may be injected into the victims through bees’ sting and the amount of venom per sting ranges between 50 and 140 μg (Moreno and Giralt, 2015). The responses of the human organism include local and limited or systemic and extensive inflammatory reactions, immune responses and anticoagulant effects (Eze et al., 2016; Cornara et al., 2017).

The most successful drugs developed by the pharmaceutical industry have been isolated from plants, microbes and marine organisms (Ratcliffe et al., 2014). However, only around 900 pharmaceutical products for human usage have been isolated from insects (Hassan et al., 2015). Regarding BV, the majority of the published works are preliminary studies developed in vitro and in vivo using animal models, mostly mice, while little evidence comes from studies performed directly to prove BV therapeutic activities in humans.

Therefore, this review aims to outline the published literature regarding the pharmacological properties and medical applications of Apitoxin and its bioactive compounds as well as to summarize some of the health concerns related to its application.

2. Bioactive compounds of bee venom and their biological effects

Recently, the investigation of bioactive compounds isolated from BV has attracted the attention of several researchers. The majority of the published reports aims to investigate the pharmacological properties of BV components using cell cultures or in animal models, while very little information comes from studies involving humans (Komi et al., 2018). Table 1 summarizes the therapeutic activities of peptides, enzymes and biogenic amines contained in Apitoxin.

**Table 1**

| Peptide/Compound | Therapeutic Activity |
|------------------|---------------------|
| Melittin (MLT)   | Antioxidant activity, anti-inflammatory, analgesic, antihypertensive, antimicrobial, antithrombotic, anti-angiogenic, anti-cancer, antiviral, anti-fungal, anti-bacterial, anti-parasitic, anti-pyretic, anti-ulcer, anti-oxidative, anti-inflammatory, anti-allergic, anti-arthritic, anti-bacterial, anti-viral, anti-fungal, anti-parasitic. |
| Apamin           | Anti-inflammatory, analgesic, anti-oxidative, anti-allergic, anti-arthritic, anti-bacterial, anti-viral, anti-fungal, anti-parasitic. |
| Mast-Cell-Degranulating peptide (MCD) | Anti-inflammatory, analgesic, anti-oxidative, anti-allergic, anti-arthritic, anti-bacterial, anti-viral, anti-fungal, anti-parasitic. |
| Melittin F       | Anti-inflammatory, analgesic, anti-oxidative, anti-allergic, anti-arthritic, anti-bacterial, anti-viral, anti-fungal, anti-parasitic. |
| Diodep           | Anti-inflammatory, analgesic, anti-oxidative, anti-allergic, anti-arthritic, anti-bacterial, anti-viral, anti-fungal, anti-parasitic. |
| Procamine A      | Anti-inflammatory, analgesic, anti-oxidative, anti-allergic, anti-arthritic, anti-bacterial, anti-viral, anti-fungal, anti-parasitic. |
| Procamine B      | Anti-inflammatory, analgesic, anti-oxidative, anti-allergic, anti-arthritic, anti-bacterial, anti-viral, anti-fungal, anti-parasitic. |
| Pamine           | Anti-inflammatory, analgesic, anti-oxidative, anti-allergic, anti-arthritic, anti-bacterial, anti-viral, anti-fungal, anti-parasitic. |
| Protease-inhibitors | Anti-inflammatory, analgesic, anti-oxidative, anti-allergic, anti-arthritic, anti-bacterial, anti-viral, anti-fungal, anti-parasitic. |
| Histamine        | Anti-inflammatory, analgesic, anti-oxidative, anti-allergic, anti-arthritic, anti-bacterial, anti-viral, anti-fungal, anti-parasitic. |
| Dopamine         | Anti-inflammatory, analgesic, anti-oxidative, anti-allergic, anti-arthritic, anti-bacterial, anti-viral, anti-fungal, anti-parasitic. |
| Noradrenaline    | Anti-inflammatory, analgesic, anti-oxidative, anti-allergic, anti-arthritic, anti-bacterial, anti-viral, anti-fungal, anti-parasitic. |
| Nor-epinephrine  | Anti-inflammatory, analgesic, anti-oxidative, anti-allergic, anti-arthritic, anti-bacterial, anti-viral, anti-fungal, anti-parasitic. |
| Neurotransmitters | Anti-inflammatory, analgesic, anti-oxidative, anti-allergic, anti-arthritic, anti-bacterial, anti-viral, anti-fungal, anti-parasitic. |
| Phospholipase A\textsubscript{2} (PLA\textsubscript{2}) | Anti-inflammatory, analgesic, anti-oxidative, anti-allergic, anti-arthritic, anti-bacterial, anti-viral, anti-fungal, anti-parasitic. |
| Lysophospholipase | Anti-inflammatory, analgesic, anti-oxidative, anti-allergic, anti-arthritic, anti-bacterial, anti-viral, anti-fungal, anti-parasitic. |
| Hyaluronidase    | Anti-inflammatory, analgesic, anti-oxidative, anti-allergic, anti-arthritic, anti-bacterial, anti-viral, anti-fungal, anti-parasitic. |
| Acid phosphomonoesterase | Anti-inflammatory, analgesic, anti-oxidative, anti-allergic, anti-arthritic, anti-bacterial, anti-viral, anti-fungal, anti-parasitic. |
| α-glucosidase    | Anti-inflammatory, analgesic, anti-oxidative, anti-allergic, anti-arthritic, anti-bacterial, anti-viral, anti-fungal, anti-parasitic. |
| Dipeptidyl peptidase IV | Anti-inflammatory, analgesic, anti-oxidative, anti-allergic, anti-arthritic, anti-bacterial, anti-viral, anti-fungal, anti-parasitic. |
| Vitellogenin     | Anti-inflammatory, analgesic, anti-oxidative, anti-allergic, anti-arthritic, anti-bacterial, anti-viral, anti-fungal, anti-parasitic. |
2.1. Peptide components

2.1.1. Melittin

Melittin (MLT), also known as allergen Api m4 (Hossen et al., 2017), is the main compound of BV, comprising approximately 40–60% of its dry weight. MLT (together with apamin) has been reported to be found only in bee venom produced by the genus *Apis* (Moreno and Giralt, 2015). It is a linear, amphipathic, cationic and α-helical polypeptide molecule composed of 26 amino acid residues and is soluble in water (Silva et al., 2015; Kachel et al., 2018).

Recent studies provided evidence on several biological properties of MLT (Table 1). MLT has been reported to be a very potent anti-inflammatory agent, being 100 times more potent than hydro-cortisol in animal models (Vick and Shipman, 1972; Eze et al., 2016). The anti-inflammatory activity of this compound has been explored in several settings, including acne vulgaris, neuro inflammation, atherosclerosis, arthritis and liver inflammation (Lee and Bae, 2016).

Recent studies have shown that MLT significantly inhibits the replication of both enveloped [melittin molecules fuse with viral envelope, forming pore-like attack complexes] and non-enveloped viruses, decreasing their infectivity

| Bioactive compounds | Biological activities | References |
|---------------------|----------------------|------------|
| MLT                 | Anti-cancer (solid tumours) | Li et al. (2006); Liu et al. (2016a); Ip et al. (2012); Jeong et al. (2014); Jin et al. (2018); Jo et al. (2012); Kong et al. (2016); Mahmoodzadeh et al. (2015); Moreno and Giralt (2015); Rady et al. (2017); Ratcliffe et al. (2014); Shin et al. (2013); Su et al. (2015); Zarrinnahad et al. (2018); Park et al. (2010); Lee et al. (2018); Wang et al. (2009); Wang et al. (2017); Zhang et al. (2014); Zhang et al. (2016) Zhang and Chen (2017) |
| Anti-cancer (hematologic malignancies) | Saini et al. (1999); Moon et al. (2006) |
| Anti-atherosclerotic | Jeong et al. (2012); Cho et al. (2013) |
| Anti-arthritis | Jeong et al. (2015) |
| Anti-inflammatory | Ip et al. (2012); Jeong et al. (2014); Jin et al. (2018); Jo et al. (2012); Kong et al. (2016); Leandro et al. (2015); Liu et al. (2016a); Mahmoodzadeh et al. (2015); Moreno and Giralt (2015); Rady et al. (2017); Su et al. (2015); Zarrinnahad et al. (2018) |
| Antimicrobial | Ip et al. (2012); Jeong et al. (2014); Jin et al. (2018); Jo et al. (2012); Kong et al. (2016); Leandro et al. (2015); Liu et al. (2016a); Mahmoodzadeh et al. (2015); Moreno and Giralt (2015); Rady et al. (2017); Su et al. (2015); Zarrinnahad et al. (2018); Leandro et al. (2015); Moga et al. (2018); Shi et al. (2016); Shin et al. (2017) |
| Antiviral | Hood et al. (2013); Jallok et al. (2014); Leandro et al. (2015); Moga et al. (2018); Wachinger et al. (1998) |
| Pro-apoptotic | Yang et al. (2007); Han et al. (2014); Lee et al. (2014); Leandro et al. (2015); Kim et al. (2018); Moga et al. (2018) |
| Analgesic | Ahn et al. (2016) |
| Anti-fibrotic | Shin et al. (2017) |
| Anti-diabetic | Hossen et al. (2017) |
| Haemolysis | Tosteson et al., (1985) |
| Neuro-protective | Han et al. (2014) |
| Apamin | Antifungal | Shin et al. (2017) |
| Anti-fibrotic | Park et al. (2014) |
| Anti-cancer (solid tumours) | Ratcliffe et al. (2014) |
| Anti-inflammatory | Kim et al. (2017a); Shin et al. (2017) |
| Anti-atherosclerotic | Kim et al. (2015) |
| Antibacterial | Leandro et al. (2015) |
| Suppresses biliary fibrosis | Kim et al. (2017b) |
| PLA2 | Antitussive | Boultran et al. (2008); Leandro et al. (2015) |
| Anti-arthritis | Eze et al. (2016) |
| Anti-trypanosomiasis | Boultran et al. (2008) |
| Neuroprotective | Jeong et al. (2011) |
| Anti-malarial | Deregnacourt and Schrével (2000) |
| Anti-cancer | Ratcliffe et al. (2014); Wang et al. (2009) |
| Anti-HIV | Fenard et al. (2001), Ratcliffe et al. (2014) |
| Secapin | Antifungal | Lee et al. (2016a) |
| Anti-inflammatory | dos Santos-Pinto et al. (2018); Moga et al. (2018); Nitecka-Buchta et al. (2014); Komi et al. (2018) |
| Anti-atherosclerotic | Adolapin |
| Anti-nociceptive | Anti-atherosclerotic |
| Anti-inflammatory | Apidaecin |
| Anti-trypanosomiasis | Protease inhibitor |
| Antibacterial | Antifungal |
| Anti-inflammatory | Haemostasis |
| Inward-rectifier K⁺ channel blocker | Tertiapin |
| Beta adrenergic blocker, anti-anxiety | Cardiopep |
| Mast cell degranulation, histamine release | |
| Anti-inflammatory | PLA2 |
| Allergic response and Hypersensitivity | |
| Enhance the noxious action of substances | |
| Use in BV immunotherapy | |
| Embryogenesis, angiogenesis, diffusion of toxins and drugs, metastasis | |
| Histamine | Allergic response | Eze et al. (2016) |
| Local and systemic inflammation | }
through surface charge interaction.

This compound is also cytotoxic against cancer cells among other mechanisms through the activation of apoptotic pathways (both caspase-dependent and caspase-independent) and PLA2 pathways (Lee et al., 2018; Jin et al., 2018; Shin et al., 2017; Zhang and Chen, 2017; Wang et al., 2017). Indeed, the growth inhibitory potential and the capacity to suppress tumour metastasis of MLT has been observed in several types of cancer cells like liver, renal, prostate, breast, lung, bladder, gastric and leukemia, suggesting that it may be a potent agent to use in chemotherapy (Liu et al., 2016; Moreno and Giralt, 2015; Kong et al., 2016).

Melittin has also been shown to induce neural plastic changes in pain-signalining pathways by sensitization and activation of nociceptor cells (Webbe et al., 2019).

A schematic representation of the action mechanisms of some biological effects of MLT (anticancer, anti-inflammatory, antimicrobial and anti-nociceptive) are presented in Fig. 1.

In spite of the promising properties that are attracting much interest from pharmacological and biotechnological fields, MLT (whose initial structure is helical, when embedded in a lipid bilayer) can change to a dimeric form that destabilizes and alters artificial lipid bilayers containing dioleoylphosphatidylcholine (Somwongin et al., 2018). Therefore, MLT may induce morphologic changes in a dose-dependent manner, being a nonselective cytolytic peptide that may induce the lysis of red blood cells and human peripheral blood lymphocytes, among others (Gajski et al., 2016). Indeed, while in small doses MLT has anti-inflammatory effects, increases capillary permeability, in higher doses it may cause inflammation, itching, irritation and local pain (Lee and Bae, 2016). According to the literature, this compound may cause slight, moderate and severe irritation at 0.5mg/ml, 1mg/ml and concentrations above 2mg/ml, respectively (Somwongin et al., 2018). The mechanism underlying toxicity is based in the disruption of phospholipid bilayers which lead to mast cells’ lysis and the release of compounds like lysosomal enzymes, histamine and serotonin, triggering pain and inflammation. Therefore, MLT together with hyaluronidase and PLA2, are responsible for venom allergenic properties breaking up membranes cells and enhancing their cytotoxic effect (Kachel et al., 2018).

Attempts have been made to avoid these side effects via phosphorylation of MLT in specific amino acid residues; the peptide phosphorylated in 18Ser elicited lower allergenic responses when compared to native melittin. In addition, ongoing studies are assessing MLT incorporation into nanoparticles in order to decrease its the nonspecific lytic activity (Abd El-Wahed et al., 2018).

2.1.2. Apamin

Apamin is a neurotoxin with 18 amino acid residues that comprises 2–3% of BV dry weight (Rady et al., 2017; Moga et al., 2018). As mentioned previously, apamin and MLT are “species specific” compounds whose presence has only been reported in the BV of the Apis genus (Moreno and Giralt, 2015). Apamin is permeable to the blood–brain barrier, affecting the central nervous system (CNS) and producing hyperactivity and convulsions. It is well known that this peptide is as a specific and high-affinity blocker of small-conductance Ca2+-activated K+ channels (SK-channels) (Kim et al., 2017a; Zhang et al., 2018). Peripherically, apamin selectively and potently affects the potassium permeability of muscle cells membranes and, when in high doses, may cause muscle spasms and respiratory failure. This characteristic has been widely explored and apamin has been used in the literature to identify the activity of the SK-channels in different cells such as visceral smooth muscle, microglial cells, adrenal cortex, hepatocytes and ventricle cells (Voos et al., 2017). In spite of this, recent studies demonstrated that this compound is also capable of inhibiting the channel Kv1.3 with high affinity (Voos et al., 2017). These two types of channel are frequently co-expressed in different tissues among which immune system cells (T cells, macrophages and dendritic cells).

Several researchers studied health-related applications of Apamin (Table 1) as anti-inflammatory (Shin et al., 2017), antibacterial, antifungal, anti-fibrotic (Shin et al., 2017), anti-cancer (Ratcliffe et al., 2014), anti-atherosclerosis (Kim et al., 2015), anti-nociceptive and

![Fig. 1. Schematic representation of the action mechanisms of some biological effects of melittin.](image-url)
cytotoxic against cancer cells (Son et al., 2007). It has also been reported to protect undamaged neurons but also to be able to restore the function of silent ones (Moreno and Giralt, 2015). In mice models with cholestatic liver disease apamin suppressed the deposition of collagen and the expression of fibrogenic genes (Kim et al., 2017b), suggesting its role has a potential therapeutic target.

2.1.3. Mast-cell-degranulating peptide

Mast cell degranulating (MCD), also known as peptide 401, (Cherniack andGovorushko, 2018), is another important compound with 22 amino acids and two disulphide bridges which comprises around 3% of BV dry weight. It promotes mast-cells degranulation, triggering inflammatory reactions (Rady et al., 2017; Komi et al., 2018). MCD has unique immunologic properties, causing histamine release at concentrations of less than 0.1 mg/mL while acting as an anti-inflammatory compound at higher concentrations (Moga et al., 2018). Indeed, MCD has been recognized as a potent anti-inflammatory agent (Moreno and Giralt, 2015). This compound is also a neurotoxin by blocking fast-inactivating and slow-inactivating calcium-activated potassium channels (KC-channels), therefore increasing neuronal excitability (Cornara et al., 2017). However, the effects in the CNS are poorly studied (Chen et al., 2016).

2.1.4. Secapin

Secapin, comprising only 0.5–2% of BV dry weight, is a potent neurotoxin containing 25 amino acid residues and a disulphide bridge between Cys 9 and Cys 20 (Rady et al., 2017). It is a serine protease inhibitor-like peptide with anti-fibrinolytic (plasmin inhibitor), anti-elastolytic, anti-fungal and antibacterial activities; nevertheless, the mechanisms underlying such actions are poorly understood (Lee et al., 2016).

2.1.5. Adolapin

Adolapin is a basic polypeptide with 103 amino acid residues, representing 0.5–1% of BV dry weight matter (Rady et al., 2017). This compound has been reported to be anti-inflammatory, anti-nociceptive and anti-pyretic, mainly due to the inhibition of cyclooxygenase (COX), PLA₂ and lipooxygenase, thereby, prostaglandin synthetase system, following a biphasic dose-response relationship (Moga et al., 2018; Nitecka-Buchta et al., 2014; Komi et al., 2018).

2.1.6. Apidaecin

Apidaecin-type peptides are a series of small proline-rich peptides containing 18 to 20 amino acid residues (Li et al., 2006a). This non-helical and heat-stable compound is active against a wide range of human pathogens and plant-associated bacteria, through a bacteriostatic process (Van Vaerenbergh et al., 2013). These compounds are the largest group of proline-rich antimicrobial peptides known to date and appear to be non-toxic to human and animal cells, making them potential candidates for the development of new antimicrobials in the future (Li et al., 2006a).

2.1.7. Protease inhibitor

The protease-inhibitor comprises 0.1–0.8% of BV dry weight and has been reported to have anti-inflammatory and anti-fibrinolytic effects (Eze et al., 2016). Other studies revealed anti-microbial activity against fungi, gram-positive and gram-negative bacteria (Yang et al., 2017).

2.1.8. Tertiapin

Tertiapin comprises < 0.1% of BV dry weight and is a small pre-synaptic peptide with 21 amino acids that blocks inward rectifier KC channels expressed in heart, epithelial cells and CNS (dos Santos-Pinto et al., 2018; Rady et al., 2017). Despite being classified as a neurotoxin (as occurs for MCD and secapin), the information on its pharmacological and toxicological effects in the CNS is quite limited (Chen et al., 2016). Nowadays, tertiapin is used only for K⁺ channel modulation; in the future it is expected to be useful for treating disorders in atrio-ventricular transmission (Cornara et al., 2017).

2.1.9. Cardiopep

Cardiopep is a peptide comprising less than 0.7% of BV dry matter (Moreno and Giralt, 2015) reported to possess beta adrenergic and anti-arrhythmic effects (Vick et al., 1974).

2.1.10. Other peptides

Other minor constituents of BV are pamin (1–3% of dry weight matter), procamine A, B (1–2%), and melittin F, a fragment of MIL in which the first seven residues from the N terminus are missing (< 0.1%) (Chen et al., 2016; Rady et al., 2017).

2.2. Proteins

2.2.1. Phospholipase A₂ (EC 3.1.1.4)

Phospholipase A₂ has been reported to be the most abundant enzyme of BV, corresponding to 10–12% of its dry weight matter (dos Santos-Pinto et al., 2018). Due to its high molecular weight and strong antigenicity, this enzyme has been pointed as the major cause of the systemic allergic reactions to BV (Gajski et al., 2016; Hossen et al., 2016). On the other hand, several recent reports unveiled the potentiality of PLA₂ in the treatment of human disorders (Table 1) including Parkinson’s disease, asthma, several types of cancer, as well as immune mediated disorders like cisplatin-induced nephrotoxicity, hepatotoxicity and Lupus nephritis (Ratliff et al., 2014). Its role in bacteria and parasite infections was also described. For instance, Bouchin et al. (2008) observed that PLA₂ inhibited Gram-negative bacteria and the parasitic protozoan Trypanosoma brucei. This study also confirmed the antibacterial activity against Escherichia coli, Enterobacter cloacae and Citrobacter freundii (Bouchin et al., 2008). Burkholderia pseudomallei, Staphylococcus aureus, Streptococcus salivarius and Lactobacillus casei.

2.2.2. Hyaluronidase (EC 3.2.1.35)

Hyaluronidase is widely distributed in nature, particularly in animal venoms such as bee, scorpion, wasp, spider, fish and crustaceans (Bordon et al., 2015). This enzyme is composed by 350 amino acids and specifically degrades hyaluronic acid in the extracellular matrix of skin matrix, allowing the penetration of venom components deeply into the blood stream (Marković-Housley et al., 2000). Other roles of hyaluronidase in envenoming process are cell membrane disruption, pore formation, mast cell degranulation (dos Santos-Pinto et al., 2018), dilatation and increased permeability of blood vessels (Hossen et al., 2016). This enzyme is the second major allergen of BV (following Phospholipase A₂), comprising 1–2% of dry weight matter (Cornara et al., 2017). Even though hyaluronidase has little toxicity it can enhance the effect of other toxins present in venoms, contributing to the local and systemic effects of envenoming (Bordon et al., 2015).

Regarding the application of hyaluronidas for human health, these may act as an adjuvant to enhance the absorption and dispersion of injected drugs, be used in ophthalmologic surgeries and in the treatment of diseases associated with excessive “ground substance”, either applied subcutaneously or in a topical way (Reitinger et al., 2008). These enzymes may also play a role in various physiological mechanisms like angiogenesis, embryogenesis, metastasis formation, cicatrization and in several inflammatory settings like pneumonia, meningitis and sepsis (Bordon et al., 2015).

2.2.3. Acid phosphomonoesterase (EC 3.1.3.2)

The acid phosphomonoesterase, also known as acid phosphatase, is a glycoprotein and potent allergen found in BV, representing approximately 1–2% of its dry weight matter (Rady et al., 2017). This compound has been reported as a stronger elicitor of histamine release from basophils of sensitized humans. However, the pathophysiological role
of this enzyme following BV inoculation remains largely unexplored. Even so, some reports exist regarding the potential for immunotherapy against BV (Hossen et al., 2016).

2.2.4. Dipeptidyl peptidase IV

Dipeptidyl peptidase IV (Api m 5) is present in BV in low concentrations (< 1% of dry weight) and has been identified as one of the proteins of higher molecular weight (102 kDa). It appears to be responsible for the cross-reactivity between bees and wasps’ venoms (Antolín-Amérigo et al., 2017).

This proteolytic enzyme cleaves N-terminal dipeptides from polypeptides with proline or alanine in the penultimate position, what leads to the activation of BV components and promotes hypersensitivity reactions (dos Santos-Pinto et al., 2018).

2.2.5. Vitellogenin

Vitellogenin is another allergen found in BV, present in larger amounts in the BV secreted by honeybee queens. This enzyme is believed to be involved in several processes such as hormone signalling, food-related behaviour, stress resistance, immunity and longevity (dos Santos-Pinto et al., 2018), yet the underlying mechanisms remain unclear (Blank et al., 2013). Its role in the hypersensitive reactions has also been reported (dos Santos-Pinto et al., 2018).

2.2.6. Other proteins

Several proteins are present in BV in low concentrations, comprising < 1% of its dry weight matter: Lyso phospholipase (EC 3.1.1.5) also known as phospholipase B (Hossen et al., 2016; Rady et al., 2017) and α-D-Glucosidase (EC 3.2.1.20) (Hossen et al., 2016; Rady et al., 2017). To date, their biological activities are poorly documented.

2.3. Biogenic amines

2.3.1. Histamine

This small molecule comprises 0.5–2% of BV dry weight matter and is the major component among the category of biogenic amines (Moreno and Giralt, 2015). During bee venom allergy, histamine is the principal inflammatory mediator released immediately in the skin, mainly mediated by mast cell degranulation peptide. This amine promotes capillary leakage, causes itching, swelling and pain (Rady et al., 2017).

2.3.2. Dopamine and noradrenaline

Dopamine and noradrenaline are also low molecular weight compounds found in BV comprising < 1% of its dry weight matter (Rady et al., 2017). These compounds are ionotropic agents and have been pointed out to be protease inhibitors, playing a role in haemostasis and acting as anti-inflammatory agent (Nitecka-Buchta et al., 2014).

2.4. Other components

BV also contains amino-acids (like γ-aminobutyric acid and α-amino acids), carbohydrates and pheromones (iso-pentyl acetate, n-butyl acetate, iso-pentanol, n-hexyl acetate, n-octyl acetate, 2-nonanol, n-decyl acetate, benzyl acetate, benzyl (Rady et al., 2017).

3. Therapeutic applications of bee venom in human health

The use of bee products (honey, pollen, propolis, bees’ wax, royal jelly and bee venom) to treat some human illnesses is known as apitherapy and dates back from thousands of years, with their healing properties being cited in many religious texts (Cornara et al., 2017). BV has been used since around 3000 BC in ancient Egypt and Greece (Yang et al., 2017; Lee et al., 2018). Throughout the decades the use of apitherapy expanded from the Eastern to the Western countries, being currently practiced all over the world (El-Wahab and Elta, 2015), mostly as a complement to the conventional medicine practices. Notwithstanding, the understanding of the chemical composition and actions of BV dates back only 50 years ago (Moreno and Giralt, 2015).

Depending on the health condition under treatment BV can be used topically (by applying a cream, liniment, or ointment), via injection, either through acupuncture or directly through a live bee sting. Currently, the most commonly used method is BV acupuncture, which consists in the injection of diluted bee venom into acupuncture points (Lee et al., 2015).

In the last decade, as result of increasing investigation worldwide, the usefulness of BV has been reported for several diseases and pathologic contexts (Table 2), in studies performed in vitro and in vivo, in animal models or enrolling humans. Among other settings, the effects of BV were demonstrated in multiple sclerosis and Parkinson’s disease (Ostrovsky and Ehrlich, 2018), dementia (Silva et al., 2015), atherosclerosis (Lee and Bae, 2016), osteoarthritis (Lee et al., 2012), human immunodeficiency virus (HIV) (Jallouk et al., 2014), periodontitis (Gu et al., 2019), Diabetes mellitus (Hossen et al., 2017) and rheumatoid arthritis (Son et al., 2007; Brito et al., 2018). The effects of BV and its isolated bioactive compounds have also been described in several types of solid cancer like breast, ovarian, bladder, lung, liver and prostate, as well as on hematologic malignancies (Moga et al., 2018). Other therapeutic activities described are antibacterial, anti-fibrosis and anti-nociceptive (Cho et al., 2018; Cornara et al., 2017). One of the best documented effects of BV is its powerful anti-inflammatory activity, which is particularly due to the presence of melittin. Indeed, even though BV may produce local inflammation when delivered in high doses, when used in controlled concentrations it has potent anti-inflammatory effects by influencing endogenous cortisol production and suppressing inflammatory mediators among which tumour necrosis factor alpha (TNF-α) and interleukin 1-β (Lee and Bae, 2016). This property is very relevant having into account the important role of chronic inflammation in the pathogenesis of a wide range of conditions like cardiovascular diseases, obesity and diabetes, asthma, autoimmune disorders, inflammatory bowel disease and neurological diseases.

In addition, due to its anti-ageing properties, BV has been increasingly more used in the manufacture of cosmetics products (Choi et al., 2015). All of these biological activities are related to the presence of some bioactive compounds mainly the MLT, PLA2 apamin, secapin, tertiapin and MCD (Zarrinnahad et al., 2018).

In this context, this natural product and its isolated components are valuable resources to be used in the future for the design and development of drugs. However, besides the fact that the BV concentration that allows maximising the beneficial effects while decreasing the adverse ones remains unknown, many of the active compounds are far from being explored (Uddin et al., 2016). In addition, the toxicity of BV remains a big dilemma for researchers and clinicians; indeed, while small compounds and peptides mainly mediate local reactions causing discomfort, larger proteins are involved in direct tissue damage or in systemic hypersensitive reactions including anaphylaxis (Jakob et al., 2017). Thereby, yet much information is available regarding the potential applications of BV, further studies must be developed to clarify the optimum dose, its adverse effects (particularly on risk groups like pregnant and breast-feeding women) and the possible interactions with conventional drugs. A graphical overview of current strengths, weaknesses, opportunities and threats of bee venom is depicted in Fig. 2.

4. Applications of bee venom in the cosmetic industry

BV has several promising properties that aroused the interest of the dermatocosmetic industry (Komi et al., 2018). Indeed, besides its antimicrobial, antibacterial and anti-inflammatory properties, some studies reported the potentiality of BV to reduce skin aging manifestations such as skin tone changes, wrinkles, sagging and evenness (Choi et al., 2015). Notwithstanding, the potential to cause skin irritation could be a major concern (Somwong et al., 2018).
Table 2
Pharmacological activities and medical applications of Apitoxin.

| Effects of bee venom                                      | References                                                                 |
|-----------------------------------------------------------|---------------------------------------------------------------------------|
| Amyotrophic lateral sclerosis                             | Lee and Bae (2016) [in vivo, animal models]                                |
| Anti-ageing                                               | Choi et al. (2015) [in vivo, humans; in vitro]; Han et al. (2013a) [in vivo, humans; in vitro]; Tusiimire et al. (2015) [in vitro]; Han et al. (2015) [in vivo, humans; in vitro]; Lee et al. (2015) [in vitro] |
| Anti-arthritis                                             | Lee et al. (2012a); Wang et al. (2002a); Jeong et al. (2015); Son et al. (2007) [all studies performed in vivo, in humans]; |
| Anti-diabetes                                              | Prakash and Bhargava (2014) [in vivo]                                     |
| Anti-fibrotic                                              | Lee et al. (2015) [in vivo, animal models]                                 |
| Anti-inflammatory                                         | Sobral et al. (2016); Kim et al. (2016); Mohammadi et al. (2015) [all performed in vitro] |
| Anti-innocipitive                                         | Cornara et al. (2017); Sun et al. (2007) [both in vivo]                   |
| Anti-atherosclerotic                                       | Moreno and Giralt (2015); Lee and Bae (2016) [both in vivo]              |
| Anticancer (hematologic malignancies)                     | Safaeinejad et al. (2013) [in vitro]; Mohseni-Kouchesfahani et al. (2017); Moga et al. (2018) [all performed in vitro] |
| Anticancer (solid tumours)                                | Son et al. (2007); Liu et al. (2016); Park et al. (2011); Cornara et al. (2017); Ip et al. (2008); Jo et al. (2012); Kim et al. (2015a); Orslolik (2009); Choi et al. (2014); Gajski et al. (2016); Tu et al. (2008); Lee et al. (2015b); Wang et al. (2015); Sisakht et al. (2017); Jung et al. (2018); Moga et al. (2018) [all performed in vitro] |
| Antidiabetic                                               | Han et al. (2016); Lee (2016); Hegazi et al. (2017); Al-Safer et al. (2018); Park et al. (2018) [all performed in vitro] |
| Antimutagenic                                              | Varanda et al. (1999); Cornara et al. (2017) [all performed in vitro]     |
| Antioxidant                                               | Sobral et al. (2016); Somwongin et al. (2018) [all performed in vitro]    |
| Antiproliferative and cytotoxic                           | Gilmez et al. (2017); Sobral et al. (2016) [all performed in vitro]       |
| Antiviral                                                  | Hassan et al. (2015); Hood et al. (2013); Kim et al. (2015a); Wiesinger et al. (1998), Jallouk et al. (2014) [all performed in vitro] |
| Apoptosis                                                 | Moon et al. (2006); Jang et al. (2000); Park et al. (2014); Ip et al. (2008); Doo et al. (2012); Choi et al. (2014); Sisakht et al. (2017) [all performed in vitro] |
| Alleviating post-stroke shoulder pain                     | Cho et al. (2013a) [in vivo, humans]                                     |
| Chemotherapy-induced peripheral neuropathy                | Park et al. (2012); Yoon et al. (2012) [in vivo, humans]                  |
| Chronic osteoarticular pain                               | Shin et al. (2012); Sso et al. (2017) [in vivo, humans]                  |
| Complex regional pain syndrome                            | Kim et al. (2014) [in vivo, humans]                                      |
| Depression                                                | El-Wahab et al. (2015); Cherniak and Govorushko (2018) [in vivo, humans] |
| Lateral epicondylitis of the elbow                        | Jung et al. (2014) [in vivo, humans]                                     |
| Neuro-protective                                          | Doo et al. (2012); Jung et al. (2015); Hwang et al., 2015 [all performed in vitro] |
| Parkinson’s disease                                       | Cho et al. (2018); Hwang et al., 2015; Ostrovsky and Ehrlich (2018); Kim and Jeon (2014); Lee and Bae (2016) [in vivo, humans] |
| Periodontitis                                              | Kim et al. (2018); Gu et al. (2019) [both in vitro]                      |
| Postherpetic neuralgia                                     | Lee et al. (2014a) [in vivo, humans]                                     |
| Radio-protective                                          | Cornara et al. (2017); Gajski et al. (2016) [in vitro]                   |
| Rheumatoid arthritis                                      | Son et al. (2007); Lee et al. (2003); Lee et al. (2003a); Brito et al. (2018) [all performed in vivo, using animal models] |
| Sexual dysfunction                                         | Lee and Yu (2014) [in vivo, humans]                                      |
| Skin disease (acne vulgaris)                              | Han et al. (2013a); Han et al. (2016a); Kim et al. (2015) [in vivo, in humans]; |

Fig. 2. Graphical overview of apitoxin composition, strengths, weaknesses, opportunities and threats.
Han et al. (2013a) observed that cosmetics containing purified BV had a better efficiency in reducing microorganisms’ concentration and the number of skin lesion, suggesting that purified BV could be a good candidate for developing new formulations for acne vulgaris treatment. Later, Han et al. (2015) made it possible to objectify BV efficacy in terms of reducing wrinkle count, area, and depth in subjects with photodamaged skin. Also, these authors stated that the irritation potential is negligible and that long-term treatment with bee venom-containing cosmetics was safe.

Current, the majority of the cosmetic products available on the market do not mention exactly the content of BV, being marketed as containing “purified bee venom” or “bee venom extracts” without further specification. Efforts must be done in order to invest in products’ standardization and labelling, in order to overcome this very important limitation. Indeed, a method for the detection and quantification of melittin, as a marker of BV concentration, was developed by Tusiimire et al. (2015).

5. Bee venom: safety and practical considerations

During the bee sting a small amount of BV is injected into the victim (maximum of 0.3 mg per sting). The severe allergic reactions, which among insects are most frequently induced by the order hymenoptera, are more often related to IgE-mediated reactions induced by allergens rather than to the direct toxic activity of other venom components (dos Santos-Pinto et al., 2018). To date, the main allergens found in BV are phospholipase A2 (Api m1), hyaluronidase (Api m2), acid phosphomonoesterase (Api m3), melittin (Api m4), dipeptidyl dipeptidase IV (Api m5), protease inhibitor (Api m6), CUB serine protease 1 (Api m7), carboxylesterase (Api m8), serine carboxypeptidase (Api m9), icarapin (Api m10), major royal jelly protein 9 (Api m 11.0101 & Api m 11.0201) and vitellogenin (Api m12) (Kolacze et al., 2017). According to the International Union of Immunological Societies (IUIS), Phospholipase A_2, hyaluronidase and apamin are the major allergens contained in BV (Tusiimire et al., 2015; Park et al., 2015; Lee et al., 2018). These compounds induce changes in cell membranes, degrade hyaluronic acid, enhance toxins’ spreading into tissues and play a role in the destruction of extracellular matrix, among other mechanisms (Reitinger et al., 2008).

According to the literature, more than 50% of the general population has IgE reactivity to the major allergens of BV which can cause a spectrum of allergic reactions, which usually appear within 10 min (Vazquez-Revuelta and Madrigal-Burgaleta, 2018). The reactions induced by BV affect the skin but also the gastrointestinal, respiratory and cardiovascular systems, ranging from mild, local swelling to systemic and severe reactions that in some cases can even be life-threatening (Marković-Housley et al., 2000).

Even though it has been reported that venom immunotherapy is effective in the majority of Hymenoptera venom allergic patients, early and late side effects to the injections have been found in 20–40% of the patients (Blank et al., 2013). The most common early side effect is the acute local reaction, followed by weakness and dyspnoea; rhinitis and abdominal pain are more common as late side effects (Kolacze et al., 2017).

In order to ensure patients’ safety and to take advantage of the potentialities of BV while reducing the side effects, some researchers suggest the removal of the allergens PLA_2, hyaluronidase, acid phosphomonoesterase and apamin (Brito et al., 2018). In that context, Lee et al. (2018) developed an effective strategy for MLT purification from BV which also effectively removed PLA_2 and apamin. Also, Park et al. (2013) found that the use of 50% ethanol aqueous solution for the purification and analysis of BV, the content of apamin and other allergens was significantly decreased, yet MLT was kept stable. In addition, Lee et al. (2015c) and Brito et al. (2018), by means of ultrafiltration using 10 kDa molecular weight cut-off filters, made it possible to effectively remove PLA_2.

Even though BV has promising healing properties it may cause several adverse events, whose occurrence is mostly unpredictable. Local inflammatory but also systemic reactions, among which erythema, pruritus, swelling, pain, anaphylaxis, neurological complications among other nonspecific reactions may occur (Yang et al., 2017). Therefore, the researchers and health care practitioners must be aware and pay careful attention to the safety rules regarding the BV concentration and amounts to be administered in the patients (Zhang et al., 2018).

The bee hive products have been used in the human therapeutic activities since memorable times. Concretely, the practices of acupuncture using the venom have been extensively used in Oriental medicine even though their effectiveness and safety profile is still controversial due to the limited evidence (Zhang et al., 2018).

In our days, the toxicity of BV it is a big dilemma for the researchers. Several authors reported that BV is safe for humans, allowing to take advantage of its antimicrobial (Uddin et al., 2016), anti-inflammatory, anti-wrinkle (Lee et al., 2015c), and anti-acne properties (Han et al., 2016a), among others. The topical application of BV is advantageous to the residual harmful systemic side effects (Nitecka-Buchta et al., 2014). On the other hand, several other studies raised concerns on BV toxicity (Lee et al., 2015c; Kolacze et al., 2017). A meta-analysis performed in 2015, including 145 studies, revealed that the median frequency of patients experiencing adverse events associated with BV immunotherapy was 29% (in the audit studies); and BV acupuncture had a 261% increased relative risk for the occurrence of adverse events, in comparison with normal saline injection (Park et al., 2015). Systemic reactions occurred in 14% of the patients, half of which were severe. This study concluded that adverse events related to bee venom therapy are frequent, suggesting that safety is still a limitation to take into consideration.

Gülmez et al. (2017) reported that BV is highly toxic to cancer cells but also to non-tumorigenic cells, suggesting that the use of BV in the treatment of malignant tumours should be re-evaluated due to the undesirable cytotoxicity; further studies must be performed to clarify this issue.

Recently, a case reported raised a major issue. A Spanish women of 55 years age, without clinical records of any disorder, risk factors or previous reactions of any kind to Hymenoptera, had been attending apitherapy sessions for two years with good tolerance. One day, immediately after a live bee sting the women suddenly developed dyspnoea, wheezing and loss of consciousness and, due to multiorgan failure, died a few weeks later (Vazquez-Revuelta and Madrigal-Burgaleta, 2018). According to the researchers this case is the first report of death associated to the BV therapy due to complications of severe anaphylaxis.

A recent in vivo study performed in 2018, using mice, reported that the approximate median lethal dose (LD_50) of the BV is 13.19 mg/kg (Lashein et al., 2018). The amount of BV released during a bee sting ranges between 50 and 140 μg (Moreno and Giralt, 2015), much lower than the average lethal dose. However, as previously described, it may be sufficient to trigger an anaphylactic reaction. Therefore, for each therapeutic use the optimal dose and application method must be determined, in order to ensure that the beneficial effects are not hampered by harmful adverse reactions.

Last but not the least, it is essential to ensure the safety and quality of the BV: before use, a battery of physicochemical and microbiological analysis must be performed. Attention must be paid also on the storage conditions: BV may be stored up to 12 months at room temperature or up to 24 months if kept in a cool place (2-8 °C), in the original container, unopened, in a dry place and away from strong light (Lee et al., 2015a).

6. Conclusions

Bee venom has been used since the ancient times in the treatment of different disorders. On the last decades, several studies provided
scientific evidence regarding the wide range of biological activities of Apitoxin. In spite of that, the adverse effects that not uncommonly follow BV administration are still a challenge for researchers and healthcare practitioners worldwide. Indeed, even though BV immunotherapy appears to be efficacious and safe (when used in controlled conditions), side effects related to BV therapy cannot be underscored. In addition, the generation of clinical-grade and sterile pharmaceutical products derived from BV is still challenging, mostly related to identification, isolation, and purification of bioactive components; further developments are expected. In the future, practitioners should be trained in order to optimize the BV concentrations that allow maximizing the clinical beneficial effects while avoiding adverse ones; further studies (mainly randomized controlled trials) are required.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments

A. Pascoal would like to thank Foundation for Science and Technology (FCT, Portugal), Program Operacional Pontencial Humano (POPH) and European Union (EU) for his Postdoctoral grant SFRH/ Technology (FCT, Portugal), Programa Operacional Pontencial Humano (POPH) and European Union (EU) for his Postdoctoral grant SFRH/BIA/101615/2014 and by the ERDF through POPH (FCT, Portugal), Programa Operacional Pontencial Humano (POPH) and European Union (EU) for his Postdoctoral grant SFRH/BIA/101615/2014 and by the ERDF through POPH (FCT, Portugal), Programa Operacional Pontencial Humano (POPH) and European Union (EU) for his Postdoctoral grant SFRH/BIA/101615/2014 and by the ERDF through POPH (FCT, Portugal), Programa Operacional Pontencial Humano (POPH) and European Union (EU) for his Postdoctoral grant SFRH/BIA/101615/2014 and by the ERDF through POPH (FCT, Portugal), Programa Operacional Pontencial Humano (POPH) and European Union (EU) for his Postdoctoral grant SFRH/BIA/101615/2014 and by the ERDF through POPH (FCT, Portugal), Programa Operacional Pontencial Humano (POPH) and European Union (EU) for his Postdoctoral grant SFRH/BIA/101615/2014 and by the ERDF through POPH (FCT, Portugal), Programa Operacional Pontencial Humano (POPH) and European Union (EU) for his Postdoctoral grant SFRH/BIA/101615/2014 and by the ERDF through POPH (FCT, Portugal), Programa Operacional Pontencial Humano (POPH) and European Union (EU) for his Postdoctoral grant SFRH/BIA/101615/2014 and by the ERDF through POPH (FCT, Portugal), Programa Operacional Pontencial Humano (POPH) and European Union (EU) for his Postdoctoral grant SFRH/BIA/101615/2014 and by the ERDF through POPH (FCT, Portugal), Programa Operacional Pontencial Humano (POPH) and European Union (EU) for his Postdoctoral grant SFRH/BIA/101615/2014 and by the ERDF through POPH (FCT, Portugal), Programa Operacional Pontencial Humano (POPH) and European Union (EU) for his Postdoctoral grant SFRH/BIA/101615/2014 and by the ERDF through POPH (FCT, Portugal), Programa Operacional Pontencial Humano (POPH) and European Union (EU) for his Postdoctoral grant SFRH/BIA/101615/2014 and by the ERDF through POPH (FCT, Portugal), Programa Operacional Pontencial Humano (POPH) and European Union (EU) for his Postdoctoral grant SFRH/BIA/101615/2014 and by the ERDF through POPH (FCT, Portugal), Programa Operacional Pontencial Humano (POPH) and European Union (EU) for his Postdoctoral grant SFRH/BIA/101615/2014 and by the ERDF through POPH (FCT, Portugal), Programa Operacional Pontencial Humano (POPH) and European Union (EU) for his Postdoctoral grant SFRH/BIA/101615/2014 and by the ERDF through POPH (FCT, Portugal), Programa Operacional Pontencial Humano (POPH) and European Union (EU) for his Postdoctoral grant SFRH/BIA/101615/2014 and by the ERDF through POPH (FCT, Portugal), Programa Operacional Pontencial Humano (POPH) and European Union (EU) for his Postdoctoral grant SFRH/BIA/101615/2014 and by the ERDF through POPH (FCT, Portugal), Programa Operacional Pontencial Humano (POPH) and European Union (EU) for his Postdoctoral grant SFRH/BIA/101615/2014 and by the ERDF through POPH (FCT, Portugal), Programa Operacional Pontencial Humano (POPH) and European Union (EU) for his Postdoctoral grant SFRH/BIA/101615/2014 and by the ERDF through POPH (FCT, Portugal), Programa Operacional Pontencial Humano (POPH) and European Union (EU) for his Postdoctoral grant SFRH/BIA/101615/2014 and by the ERDF through POPH (FCT, Portugal), Programa Operacional Pontencial Humano (POPH) and European Union (EU) for his Postdoctoral grant
